10.06.2014 • NewsDede WillamsstyrenicsStyron

Styron / Trinseo Finally Launches IPO

Styron, the US styrenics, latex and rubber producer also known as Trinseo, has kicked off its long awaited initial public offering on the New York stock exchange.

The former Dow Chemical business with $5.3 billion in annual sales is now majority owned to nearly 90% by private equity investor Bain Capital. Dow still holds just under 7% and the company's management the remainder.

Following the targeted sale of 10,000,000 of its ordinary shares at a price of $170-190 million altogether, 21% of the company is expected to be in public hands.

Goldman, Sachs, Deutsche Bank Securities, Citigroup and Morgan Stanley are acting as joint book-running managers and the representatives of the underwriters, assisted by several other international credit institutions. The underwriters have an option to buy up to 1.5 million additional shares.

Styron's first trial balloon about launching an ipo and changing its name to Trinseo came in 2011, when it said it hoped to raise $400 million. The plans were later withdrawn.

The company has also tried to change the names of all its subsidiaries to Trinseo, but not all have made the switch. Units that have not completed their process will continue to do business as Styron until their respective name changes are complete.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.